PAVmed subsidiary Lucid Diagnostics posts 2Q revenue of USD 1.5 million
LUCD•Coverage policy and financial results
Concert issued Lucid’s first laboratory benefit manager coverage policy for EsoGuard, already adopted by multiple client health plans.
Operating expenses were about USD 14.3 million; GAAP net loss attributable to common stockholders was about USD 14.7 million, or USD 0.08 a share.
Cash and cash equivalents totaled USD 33.4 million at June 30, 2026.
2Q revenue and test volume
PAVmed subsidiary Lucid Diagnostics posted 2Q26 revenue of USD 1.5 million from its EsoGuard esophageal DNA test.
Test volume reached 2,770 in the quarter as Lucid reported stronger commercial momentum.
Related News
Alibaba.com names Marcus Lemonis, Kickstarter CEO Everette Taylor among judges for CoCreate Pitch 2026 US final
BABA•
Apollo posts investor presentation outlining integrated asset management, retirement services strategy, USD 1 trillion AUM milestone
APO•
